Affinity DataIC50: 100nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 190nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 300nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 310nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 430nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 460nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 660nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.70E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.80E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.60E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.80E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.20E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.30E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.40E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.50E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4.10E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4.20E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4.70E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5.20E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Antagonist activity at human TRalpha assessed as inhibition of interaction with SRC2-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 7.10E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 7.40E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8.20E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8.50E+3nMAssay Description:Antagonist activity at human TRbeta assessed as inhibition of interaction with SRC2-2 after 3 hrs by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: 3.02E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma(Homo sapiens (Human))
Institut Pasteur Korea
Curated by ChEMBL
Institut Pasteur Korea
Curated by ChEMBL
Affinity DataIC50: >6.00E+4nMAssay Description:Antagonist activity at human PPAR-gamma assessed as inhibition of interaction with DRIP-2 by fluorescence polarisation assayMore data for this Ligand-Target Pair